Literature DB >> 18948497

Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet.

Bo Kong1, James P Luyendyk, Ossama Tawfik, Grace L Guo.   

Abstract

Nonalcoholic steatohepatitis (NASH) comprises dysregulation of lipid metabolism and inflammation. Identification of the various genetic and environmental susceptibility factors for NASH may provide novel treatments to limit inflammation and fibrosis in patients. This study utilized a mouse model of hypercholesterolemia, low-density lipoprotein receptor knockout (LDLr(-/-)) mice fed a high-fat diet for 5 months, to test the hypothesis that farnesoid X receptor (FXR) deficiency contributed to NASH development. Either the high-fat diet or FXR deficiency increased serum alanine aminotransferase activity, whereas only FXR deficiency increased bile acid and alkaline phosphatase levels. FXR deficiency and high-fat feeding increased serum cholesterol and triglycerides. Although high fat led to macrosteatosis and hepatocyte ballooning in livers of mice regardless of genotype, no inflammatory infiltrate was observed in the livers of LDLr(-/-) mice. In contrast, in the livers of LDLr(-/-)/FXR(-/-) mice, foci of inflammatory cells were observed occasionally when fed the control diet and were greatly increased when fed the high-fat diet. Consistent with enhanced inflammatory cells, hepatic levels of tumor necrosis factor alpha and intercellular adhesion molecule-1 mRNA were increased by the high-fat diet in LDLr(-/-)/FXR(-/-) mice. In agreement with elevated levels of procollagen 1 alpha 1 and TGF-beta mRNA, type 1 collagen protein levels were increased in livers of LDLr(-/-)/FXR(-/-) mice fed a high-fat diet. In conclusion, FXR deficiency induces pathologic manifestations required for NASH diagnosis in a mouse model of hypercholesterolemia, including macrosteatosis, hepatocyte ballooning, and inflammation, which suggest a combination of FXR deficiency and high-fat diet is a risk factor for NASH development, and activation of FXR may be a therapeutic intervention in the treatment of NASH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18948497      PMCID: PMC2685903          DOI: 10.1124/jpet.108.144600

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  48 in total

Review 1.  Mechanisms of hepatotoxicity.

Authors:  Hartmut Jaeschke; Gregory J Gores; Arthur I Cederbaum; Jack A Hinson; Dominique Pessayre; John J Lemasters
Journal:  Toxicol Sci       Date:  2002-02       Impact factor: 4.849

2.  The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression.

Authors:  N L Urizar; D H Dowhan; D D Moore
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

3.  Activation of the Raf-1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes.

Authors:  Yi-Ping Rao; Elaine J Studer; R Todd Stravitz; Seema Gupta; Liang Qiao; Paul Dent; Phillip B Hylemon
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

4.  NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome.

Authors:  Shivakumar Chitturi; Shehan Abeygunasekera; Geoffrey C Farrell; Jane Holmes-Walker; Jason M Hui; Caroline Fung; Rooshdiya Karim; Rita Lin; Dev Samarasinghe; Christopher Liddle; Martin Weltman; Jacob George
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

5.  The farnesoid X-receptor is an essential regulator of cholesterol homeostasis.

Authors:  Gilles Lambert; Marcelo J A Amar; Grace Guo; H Bryan Brewer; Frank J Gonzalez; Christopher J Sinal
Journal:  J Biol Chem       Date:  2002-11-05       Impact factor: 5.157

6.  Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes.

Authors:  Liang Qiao; Song Iy Han; Youwen Fang; Jong Sung Park; Seema Gupta; Donna Gilfor; George Amorino; Kristoffer Valerie; Linda Sealy; John F Engelhardt; Steven Grant; Philip B Hylemon; Paul Dent
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

7.  Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity.

Authors:  Grace L Guo; Gilles Lambert; Masahiko Negishi; Jerrold M Ward; H Bryan Brewer; Steven A Kliewer; Frank J Gonzalez; Christopher J Sinal
Journal:  J Biol Chem       Date:  2003-08-15       Impact factor: 5.157

8.  Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice.

Authors:  Kun L Ma; Xiong Z Ruan; Stephen H Powis; Yaxi Chen; John F Moorhead; Zac Varghese
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

9.  Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.

Authors:  Yaping Liu; Jane Binz; Mary Jo Numerick; Steve Dennis; Guizhen Luo; Bhasha Desai; Kathleen I MacKenzie; Traci A Mansfield; Steven A Kliewer; Bryan Goodwin; Stacey A Jones
Journal:  J Clin Invest       Date:  2003-11-17       Impact factor: 14.808

10.  Model of nonalcoholic steatohepatitis.

Authors:  Charles S Lieber; Maria A Leo; Ki M Mak; Youqing Xu; Qi Cao; Chaoling Ren; Anatoly Ponomarenko; Leonore M DeCarli
Journal:  Am J Clin Nutr       Date:  2004-03       Impact factor: 7.045

View more
  69 in total

Review 1.  Pericytes in the Liver.

Authors:  Enis Kostallari; Vijay H Shah
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

2.  Synbiotics Bifidobacterium infantis and milk oligosaccharides are effective in reversing cancer-prone nonalcoholic steatohepatitis using western diet-fed FXR knockout mouse models.

Authors:  Prasant Kumar Jena; Lili Sheng; Nidhi Nagar; Chao Wu; Daniela Barile; David A Mills; Yui-Jui Yvonne Wan
Journal:  J Nutr Biochem       Date:  2018-04-25       Impact factor: 6.048

Review 3.  The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Monica D Chow; Yi-Horng Lee; Grace L Guo
Journal:  Mol Aspects Med       Date:  2017-05-05

4.  Hepatocyte-specific deletion of farnesoid X receptor delays but does not inhibit liver regeneration after partial hepatectomy in mice.

Authors:  Prachi Borude; Genea Edwards; Chad Walesky; Feng Li; Xiaochao Ma; Bo Kong; Grace L Guo; Udayan Apte
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

5.  18β-Glycyrrhetinic acid protects against alpha-naphthylisothiocyanate-induced cholestasis through activation of the Sirt1/FXR signaling pathway.

Authors:  Shou-Yan Wu; Shi-Chao Cui; Le Wang; Yi-Ting Zhang; Xiao-Xia Yan; Heng-Lei Lu; Guo-Zhen Xing; Jin Ren; Li-Kun Gong
Journal:  Acta Pharmacol Sin       Date:  2018-07-30       Impact factor: 6.150

6.  An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors.

Authors:  Suriyan Ponnusamy; Quynh T Tran; Thirumagal Thiyagarajan; Duane D Miller; Dave Bridges; Ramesh Narayanan
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-16

7.  Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.

Authors:  Brett M McGettigan; Rachel H McMahan; Yuhuan Luo; Xiaoxin X Wang; David J Orlicky; Cara Porsche; Moshe Levi; Hugo R Rosen
Journal:  J Biol Chem       Date:  2016-09-07       Impact factor: 5.157

Review 8.  Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease.

Authors:  A Zarrinpar; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2012-10-11       Impact factor: 8.171

Review 9.  Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Justin D Schumacher; Grace L Guo
Journal:  Handb Exp Pharmacol       Date:  2019

10.  Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.

Authors:  Yanqiao Zhang
Journal:  Drugs Future       Date:  2010-08-01       Impact factor: 0.148

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.